⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 12, 2025Open Access

Table 2 from Drug–Drug Interaction Liabilities with BTK Inhibitor TL-895

Jack C. Stromatt Eman Ahmed Thomas Drabison Mahesh R. Nepal Anika T. Chowdhury Shelley Orwick Daelynn R. Buelow Eric D. Eisenmann Kevin M. Huang Alex Sparreboom Sharyn D. Baker

View Full Paper

Ask AI

Bookmark

Share

Key Points

TL-895 induces significant drug-drug interactions, impacting pharmacokinetics in mice.
Observed pharmacokinetic changes indicate potential for altered drug efficacy or toxicity in combination therapies.
Analysis involved pharmacokinetic assays to evaluate interactions with other drugs using mice models.
Findings support the need for careful assessment of drug combinations involving BTK inhibitors.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

Observational analysis reveals drug-drug interactions with BTK inhibitor TL-895 in mice, highlighting pharmacokinetic implications.

Abstract

Pharmacokinetic DDIs induced by TL-895 in mice

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Stromatt et al. (2025) studied this question.

synapsesocial.com/papers/68d4605131b076d99fa5fbca https://doi.org/10.1158/2767-9764.30111344

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Table 1 from Drug–Drug Interaction Liabilities with BTK Inhibitor TL-8952025
2Supplementary Figure S3 from Drug–Drug Interaction Liabilities with BTK Inhibitor TL-8952025
3Supplementary Figure S4 from Drug–Drug Interaction Liabilities with BTK Inhibitor TL-8952025
4Figure 3 from Drug–Drug Interaction Liabilities with BTK Inhibitor TL-8952025
5Data from Drug–Drug Interaction Liabilities with BTK Inhibitor TL-8952025